1. Home
  2. SHMD vs CHRS Comparison

SHMD vs CHRS Comparison

Compare SHMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

HOLD

Current Price

$6.46

Market Cap

323.0M

Sector

N/A

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.60

Market Cap

291.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHMD
CHRS
Founded
1864
2010
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.0M
291.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
SHMD
CHRS
Price
$6.46
$1.60
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
752.4K
1.3M
Earning Date
05-15-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
1.43
Revenue
N/A
N/A
Revenue This Year
N/A
$88.67
Revenue Next Year
N/A
$28.64
P/E Ratio
N/A
$1.11
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.72
52 Week High
$10.65
$2.62

Technical Indicators

Market Signals
Indicator
SHMD
CHRS
Relative Strength Index (RSI) 44.86 41.96
Support Level $2.36 $1.55
Resistance Level $6.70 $1.75
Average True Range (ATR) 0.93 0.11
MACD 0.02 -0.01
Stochastic Oscillator 19.07 14.11

Price Performance

Historical Comparison
SHMD
CHRS

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: